CRWVMEDIUM SIGNALFINANCIAL10-Q

CRWV reported substantially higher revenue growth while maintaining strong balance sheet fundamentals despite reduced cash position.

The meaningful revenue expansion indicates strong business momentum and market traction. However, the decline in cash and current assets alongside increased debt levels suggests the company may be investing heavily in growth or facing working capital challenges that warrant monitoring.

Comparing 2025-11-13 vs 2025-08-13View on EDGAR →
FINANCIAL ANALYSIS

CRWV demonstrated robust top-line growth with revenue substantially higher year-over-year, while R&D expenses grew modestly at 11.8%, indicating operational leverage. The balance sheet shows mixed signals with stockholders' equity increasing 42.7% and total assets expanding 12.7%, but cash declining 28.2% and current assets falling 25.1%. Total debt increased 16.3% to $24.9B, suggesting the company is funding operations or growth initiatives through borrowing while managing overall financial stability.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+52.3%
$1.4B$2.1B

Strong top-line growth of 52.3% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
+42.7%
$3.3B$4.8B

Equity base grew 42.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Accounts Receivable
Balance Sheet
-33.1%
$3.2B$2.1B

Receivables declined — improved collection efficiency or conservative revenue recognition.

Cash & Equivalents
Balance Sheet
-28.2%
$3.1B$2.2B

Cash decreased 28.2% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-25.1%
$7.5B$5.6B

Current assets declined 25.1% — monitor working capital adequacy and short-term liquidity.

Total Debt
Balance Sheet
+16.3%
$21.4B$24.9B

Debt rose 16.3% — additional borrowing for investment or operations; monitor coverage ratios.

Total Assets
Balance Sheet
+12.7%
$49.3B$55.6B

Asset base grew 12.7% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
+11.8%
$93.0M$104.0M

R&D investment increased 11.8% — signals commitment to future product development, though near-term margin impact.

Total Liabilities
Balance Sheet
+10.5%
$46.0B$50.8B

Liabilities increased 10.5% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2025-11-13
PRIOR — 2025-08-13
ADDED
See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
had outstanding 386,401,201 shares of Class A common stock, 111,916,311 shares of Class B common stock, and 0 shares of Class C common stock, each with a par value of $0.000005.
Management's Discussion and Analysis of Financial Condition and Results of Operations 44 Item 3.
The words "believe," "may," "will," "estimate," "potential," "continue," "anticipate," "intend," "expect," "could," "would," "project," "plan," "target," and similar expressions are intended to identify forward-looking statements.
In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject.
+7 more — sign up free →
REMOVED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
had outstanding 370,470,348 shares of Class A common stock, 118,102,040 shares of Class B common stock, and 0 shares of Class C common stock, each with a par value of $0.000005.
Managemen t ' s Discussion and Analysis of Financial Condition and Results of Operations 41 Item 3.
The words believe, may, will, estimate, potential, continue, anticipate, intend, expect, could, would, project, plan, target, and similar expressions are intended to identify forward-looking statements.
In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →